{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:32:56Z","timestamp":1794540776065,"version":"4.9.1"},"reference-count":131,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a new and effective treatment for patients with hematologic malignancies. Clinical responses to CAR T cells in leukemia, lymphoma, and multiple myeloma have provided strong evidence of the antitumor activity of these cells. In patients with refractory or relapsed B-cell acute lymphoblastic leukemia (ALL), the infusion of autologous anti-CD19 CAR T cells is rapidly gaining standard-of-care status and might eventually be incorporated into frontline treatment. In T-ALL, however, leukemic cells generally lack surface molecules recognized by established CAR, such as CD19 and CD22. Such deficiency is particularly important, as outcome is dismal for patients with T-ALL that is refractory to standard chemotherapy and\/or hematopoietic stem cell transplant. Recently, CAR T-cell technologies directed against T-cell malignancies have been developed and are beginning to be tested clinically. The main technical obstacles stem from the fact that malignant and normal T cells share most surface antigens. Therefore, CAR T cells directed against T-ALL targets might be susceptible to self-elimination during manufacturing and\/or have suboptimal activity after infusion. Moreover, removing leukemic cells that might be present in the cell source used for CAR T-cell manufacturing might be problematic. Finally, reconstitution of T cells and natural killer cells after CAR T-cell infusion might be impaired. In this article, we discuss potential targets for CAR T-cell therapy of T-ALL with an emphasis on CD7, and review CAR configurations as well as early clinical results.<\/jats:p>","DOI":"10.3324\/haematol.2023.283848","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:43:27Z","timestamp":1717213407000},"page":"1677-1688","source":"Crossref","is-referenced-by-count":43,"title":["Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Bernice L.Z.","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Vinanica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond M.H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"61313","doi-asserted-by":"crossref","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019; 20(3):e142-e154.","DOI":"10.1016\/S1470-2045(19)30031-2"},{"key":"61314","doi-asserted-by":"crossref","unstructured":"Marks DI, Paietta EM, Moorman AV. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009; 114(25):5136-5145.","DOI":"10.1182\/blood-2009-08-231217"},{"key":"61315","doi-asserted-by":"crossref","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354(2):166-178.","DOI":"10.1056\/NEJMra052603"},{"key":"61316","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2):147-156.","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"61317","doi-asserted-by":"crossref","unstructured":"Zhang J, Ding L, Holmfeldt L. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-163.","DOI":"10.1038\/nature10725"},{"key":"61318","doi-asserted-by":"crossref","unstructured":"Inukai T, Kiyokawa N, Campana D. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group study L99-15. Br J Haematol. 2012; 156(3):358-365.","DOI":"10.1111\/j.1365-2141.2011.08955.x"},{"key":"61319","doi-asserted-by":"crossref","unstructured":"Neumann M, Heesch S, Gokbuget N. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012; 2(1):e55.","DOI":"10.1038\/bcj.2011.49"},{"key":"61320","doi-asserted-by":"crossref","unstructured":"Jain N, Lamb AV, O\u2019Brien S. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016; 127(15):1863-1869.","DOI":"10.1182\/blood-2015-08-661702"},{"key":"61321","doi-asserted-by":"crossref","unstructured":"Wood B, Devidas M, Summers RJ. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood. 2023; 142(24):2069-2078.","DOI":"10.1182\/blood.2023020678"},{"key":"61322","doi-asserted-by":"crossref","unstructured":"Campana D, Pui CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood. 2017; 129(14):1913-1918.","DOI":"10.1182\/blood-2016-12-725804"},{"key":"61323","doi-asserted-by":"crossref","unstructured":"Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017; 129(9):1134-1142.","DOI":"10.1182\/blood-2016-07-692608"},{"key":"61324","doi-asserted-by":"crossref","unstructured":"Eckert C, Parker C, Moorman AV. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021; 151:175-189.","DOI":"10.1016\/j.ejca.2021.03.034"},{"key":"61325","doi-asserted-by":"crossref","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023; 614(7949):635-648.","DOI":"10.1038\/s41586-023-05707-3"},{"key":"61326","doi-asserted-by":"crossref","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Eng J Med. 2011; 365(8):725-733.","DOI":"10.1056\/NEJMoa1103849"},{"key":"61327","doi-asserted-by":"crossref","unstructured":"Grupp SA, Kalos M, Barrett D. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518.","DOI":"10.1056\/NEJMoa1215134"},{"key":"61328","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Davila ML, Riviere I. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra138.","DOI":"10.1126\/scitranslmed.3005930"},{"key":"61329","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi LA, Berger C. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6):2123-2138.","DOI":"10.1172\/JCI85309"},{"key":"61330","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"61331","doi-asserted-by":"crossref","unstructured":"Fry TJ, Shah NN, Orentas RJ. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018; 24(1):20-28.","DOI":"10.1038\/nm.4441"},{"key":"61332","doi-asserted-by":"crossref","unstructured":"Wayne AS, Huynh V, Hijiya N. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2023; 108(3):747-760.","DOI":"10.3324\/haematol.2022.280678"},{"key":"61333","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Rives S. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023; 41(9):1664-1669.","DOI":"10.1200\/JCO.22.00642"},{"key":"61334","doi-asserted-by":"crossref","unstructured":"Shah NN, Lee DW, Yates B. Long-term follow-up of CD19-CAR T-cell therapy in cchildren and young adults with B-ALL. J Clin Oncol. 2021; 39(15):1650-1659.","DOI":"10.1200\/JCO.20.02262"},{"key":"61335","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"61336","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"61337","doi-asserted-by":"crossref","unstructured":"Westin JR, Oluwole OO, Kersten MJ. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023; 389(2):148-157.","DOI":"10.1056\/NEJMoa2301665"},{"key":"61338","doi-asserted-by":"crossref","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nature Rev Clin Oncol. 2023; 20(6):359-371.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"61339","doi-asserted-by":"crossref","unstructured":"Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000; 243(1-2):59-75.","DOI":"10.1016\/S0022-1759(00)00228-3"},{"key":"61340","doi-asserted-by":"crossref","unstructured":"Jasper GA, Arun I, Venzon D. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom. 2011; 80(2):83-90.","DOI":"10.1002\/cyto.b.20567"},{"key":"61341","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, Lhermitte L, Bottcher S. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-1975.","DOI":"10.1038\/leu.2012.120"},{"key":"61342","doi-asserted-by":"crossref","unstructured":"Haso W, Lee DW, Shah NN. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013; 121(7):1165-1174.","DOI":"10.1182\/blood-2012-06-438002"},{"key":"61343","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022; 40(9):932-944.","DOI":"10.1200\/JCO.21.01405"},{"key":"61344","doi-asserted-by":"crossref","unstructured":"Campana D, Janossy G, Bofill M. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol. 1985; 134(3):1524-1530.","DOI":"10.4049\/jimmunol.134.3.1524"},{"key":"61345","doi-asserted-by":"crossref","unstructured":"Mahadeo KM, Khazal SJ, Abdel-Azim H. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Rev Clinl Oncol. 2019; 16(1):45-63.","DOI":"10.1007\/978-3-319-74698-2_200-1"},{"key":"61346","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sandlund JT, Perkins SL. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2009; 27(21):3533-2539.","DOI":"10.1200\/JCO.2008.21.1318"},{"key":"61347","doi-asserted-by":"crossref","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015; 126(8):983-992.","DOI":"10.1182\/blood-2015-02-629527"},{"key":"61348","doi-asserted-by":"crossref","unstructured":"Png YT, Vinanica N, Kamiya T. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017; 1(25):2348-2360.","DOI":"10.1182\/bloodadvances.2017009928"},{"key":"61349","doi-asserted-by":"crossref","unstructured":"Lobach DF, Hensley LL, Ho W, Haynes BF. Human T cell antigen expression during the early stages of fetal thymic maturation. J Immunol. 1985; 135(3):1752-1759.","DOI":"10.4049\/jimmunol.135.3.1752"},{"key":"61350","doi-asserted-by":"crossref","unstructured":"Campana D, van Dongen JJ, Mehta A. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 1991; 77(7):1546-1554.","DOI":"10.1182\/blood.V77.7.1546.bloodjournal7771546"},{"key":"61351","doi-asserted-by":"crossref","unstructured":"Hao QL, George AA, Zhu J. Human intrathymic lineage commitment is marked by differential CD7 expression: identification of CD7- lympho-myeloid thymic progenitors. Blood. 2008; 111(3):1318-1326.","DOI":"10.1182\/blood-2007-08-106294"},{"key":"61352","doi-asserted-by":"crossref","unstructured":"Vodinelich L, Tax W, Bai Y. A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL). Blood. 1983; 62(5):1108-1113.","DOI":"10.1182\/blood.V62.5.1108.1108"},{"key":"61353","doi-asserted-by":"crossref","unstructured":"Link M, Warnke R, Finlay J. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. Blood. 1983; 62(4):722-728.","DOI":"10.1182\/blood.V62.4.722.722"},{"key":"61354","doi-asserted-by":"crossref","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1(2):133-143.","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"61355","unstructured":"Janossy G, Coustan-Smith E, Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989; 3(3):170-181."},{"key":"61356","doi-asserted-by":"crossref","unstructured":"Haynes BF, Eisenbarth GS, Fauci AS. Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. Proc Natl Acad Sci U S A. 1979; 76(11):5829-5833.","DOI":"10.1073\/pnas.76.11.5829"},{"key":"61357","doi-asserted-by":"crossref","unstructured":"Sempowski GD, Lee DM, Kaufman RE, Haynes BF. Structure and function of the CD7 molecule. Critical Rev Immunol. 1999; 19(4):331-348.","DOI":"10.1615\/CritRevImmunol.v19.i4.40"},{"key":"61358","doi-asserted-by":"crossref","unstructured":"Bonilla FA, Kokron CM, Swinton P, Geha RS. Targeted gene disruption of murine CD7. Int Immunol. 1997; 9(12):1875-1883.","DOI":"10.1093\/intimm\/9.12.1875"},{"key":"61359","doi-asserted-by":"crossref","unstructured":"Lee DM, Staats HF, Sundy JS. Immunologic characterization of CD7-deficient mice. J Immunol. 1998; 160(12):5749-5756.","DOI":"10.4049\/jimmunol.160.12.5749"},{"key":"61360","doi-asserted-by":"crossref","unstructured":"Sempowski GD, Lee DM, Scearce RM, Patel DD, Haynes BF. Resistance of CD7-deficient mice to lipopolysaccharide-induced shock syndromes. J Exp Med. 1999; 189(6):1011-1016.","DOI":"10.1084\/jem.189.6.1011"},{"key":"61361","doi-asserted-by":"crossref","unstructured":"Reinhold U, Abken H, Kukel S. CD7- T cells represent a subset of normal human blood lymphocytes. J Immunol. 1993; 150(5):2081-2089.","DOI":"10.4049\/jimmunol.150.5.2081"},{"key":"61362","doi-asserted-by":"crossref","unstructured":"Kukel S, Reinhold U, Oltermann I, Kreysel HW. Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin Exp Immunol. 1994; 98(1):163-168.","DOI":"10.1111\/j.1365-2249.1994.tb06624.x"},{"key":"61363","doi-asserted-by":"crossref","unstructured":"Aandahl EM, Sandberg JK, Beckerman KP. CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol. 2003; 170(5):2349-2355.","DOI":"10.4049\/jimmunol.170.5.2349"},{"key":"61364","doi-asserted-by":"crossref","unstructured":"Frankel AE, Laver JH, Willingham MC. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma. 1997; 26(3-4):287-298.","DOI":"10.3109\/10428199709051778"},{"key":"61365","doi-asserted-by":"crossref","unstructured":"Baum W, Steininger H, Bair HJ. Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol. 1996; 95(2):327-338.","DOI":"10.1046\/j.1365-2141.1996.d01-1900.x"},{"key":"61366","doi-asserted-by":"crossref","unstructured":"Pauza ME, Doumbia SO, Pennell CA. Construction and characterization of human CD7-specific single-chain Fv immunotoxins. J Immunol. 1997; 158(7):3259-3269.","DOI":"10.4049\/jimmunol.158.7.3259"},{"key":"61367","doi-asserted-by":"crossref","unstructured":"Pennell CA, Pauza ME. CD7-specific single chain Fv immunotoxins. Design and expression. Methods Mol Biol. 2001; 166:17-29.","DOI":"10.1385\/1-59259-114-0:17"},{"key":"61368","doi-asserted-by":"crossref","unstructured":"Imai C, Mihara K, Andreansky M. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18:676-684.","DOI":"10.1038\/sj.leu.2403302"},{"key":"61369","doi-asserted-by":"crossref","unstructured":"Milone MC, Fish JD, Carpenito C. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-1464.","DOI":"10.1038\/mt.2009.83"},{"key":"61370","doi-asserted-by":"crossref","unstructured":"Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors. Cancer J. 2014; 20(2):134-140.","DOI":"10.1097\/PPO.0000000000000028"},{"key":"61371","doi-asserted-by":"crossref","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017; 130(3):285-296.","DOI":"10.1182\/blood-2017-01-761320"},{"key":"61372","doi-asserted-by":"crossref","unstructured":"Cooper ML, Choi J, Staser K. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018; 32(9):1970-1983.","DOI":"10.1038\/s41375-018-0065-5"},{"key":"61373","doi-asserted-by":"crossref","unstructured":"Georgiadis C, Rasaiyaah J, Gkazi SA. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021; 35(12):3466-3481.","DOI":"10.1038\/s41375-021-01282-6"},{"key":"61374","doi-asserted-by":"crossref","unstructured":"Jiang J, Chen J, Liao C. Inserting EF1alpha-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023; 37(8):1660-1670.","DOI":"10.1038\/s41375-023-01948-3"},{"key":"61375","doi-asserted-by":"crossref","unstructured":"Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018; 2(5):517-528.","DOI":"10.1182\/bloodadvances.2017012823"},{"key":"61376","doi-asserted-by":"crossref","unstructured":"Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019; 12:130.","DOI":"10.1172\/JCI123955"},{"key":"61377","doi-asserted-by":"crossref","unstructured":"Zhang M, Chen D, Fu X. Autologous nanbody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/ lymphoma. Clin Cancer Res. 2022; 28(13):2830-2843.","DOI":"10.1158\/1078-0432.CCR-21-4097"},{"key":"61378","doi-asserted-by":"crossref","unstructured":"Cameron P, Fuller CK, Donohoue PD. Mapping the genomic landscape of CRISPR-Cas9 cleavage. Nat Methods. 2017; 14(6):600-606.","DOI":"10.1038\/nmeth.4284"},{"key":"61379","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367(6481)"},{"key":"61380","doi-asserted-by":"crossref","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-424.","DOI":"10.1038\/nature17946"},{"key":"61381","doi-asserted-by":"crossref","unstructured":"Doman JL, Raguram A, Newby GA, Liu DR. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol. 2020; 38(5):620-628.","DOI":"10.1038\/s41587-020-0414-6"},{"key":"61382","doi-asserted-by":"crossref","unstructured":"Diorio C, Murray R, Naniong M. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022; 140(6):619-629.","DOI":"10.1182\/blood.2022015825"},{"key":"61383","doi-asserted-by":"crossref","unstructured":"Chiesa R, Georgiadis C, Syed F. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023; 389(10):899-910.","DOI":"10.1056\/NEJMoa2300709"},{"key":"61384","doi-asserted-by":"crossref","unstructured":"Kim D, Bae S, Park J. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods. 2015; 12(3):237-243.","DOI":"10.1038\/nmeth.3284"},{"key":"61385","doi-asserted-by":"crossref","unstructured":"Tsai SQ, Nguyen NT, Malagon-Lopez J. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods. 2017; 14(6):607-614.","DOI":"10.1038\/nmeth.4278"},{"key":"61386","doi-asserted-by":"crossref","unstructured":"Yu Y, Leete TC, Born DA. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat Commun. 2020; 11(1):2052.","DOI":"10.1038\/s41467-020-15887-5"},{"key":"61387","doi-asserted-by":"crossref","unstructured":"Grunewald J, Zhou R, Lareau CA. A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing. Nat Biotechnol. 2020; 38(7):861-864.","DOI":"10.1038\/s41587-020-0535-y"},{"key":"61388","doi-asserted-by":"crossref","unstructured":"Lam DK, Feliciano PR, Arif A. Improved cytosine base editors generated from TadA variants. Nat Biotechnol. 2023; 41(5):686-697.","DOI":"10.1038\/s41587-022-01611-9"},{"key":"61389","doi-asserted-by":"crossref","unstructured":"Watanabe N, Mo F, Zheng R. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023; 31(1):24-34.","DOI":"10.1016\/j.ymthe.2022.09.003"},{"key":"61390","doi-asserted-by":"crossref","unstructured":"Mestermann K, Giavridis T, Weber J. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Trnasl Med. 2019; 11(499):eaau5907.","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"61391","doi-asserted-by":"crossref","unstructured":"Weber EW, Lynn RC, Sotillo E. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019; 3(5):711-717.","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"61392","doi-asserted-by":"crossref","unstructured":"Lu P, Liu Y, Yang J. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022; 140(4):321-334.","DOI":"10.1182\/blood.2021014498"},{"key":"61393","doi-asserted-by":"crossref","unstructured":"Freiwan A, Zoine JT, Crawford JC. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022; 140(25):2684-2696.","DOI":"10.1182\/blood.2021015020"},{"key":"61394","doi-asserted-by":"crossref","unstructured":"Jones NH, Clabby ML, Dialynas DP. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1. Nature. 1986; 323(6086):346-349.","DOI":"10.1038\/323346a0"},{"key":"61395","doi-asserted-by":"crossref","unstructured":"Tembhare PR, Chatterjee G, Khanka T. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. Cytometry B Clin Cytom. 2021; 100(4):421-433.","DOI":"10.1002\/cyto.b.21939"},{"key":"61396","doi-asserted-by":"crossref","unstructured":"Raikar SS, Fleischer LC, Moot R. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. Oncoimmunology. 2018; 7(3):e1407898.","DOI":"10.1080\/2162402X.2017.1407898"},{"key":"61397","doi-asserted-by":"crossref","unstructured":"Dai Z, Mu W, Zhao Y. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021; 29(9):2707-2722.","DOI":"10.1016\/j.ymthe.2021.07.001"},{"key":"61398","doi-asserted-by":"crossref","unstructured":"Mamonkin M, Mukherjee M, Srinivasan M. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018; 6(1):47-58.","DOI":"10.1158\/2326-6066.CIR-17-0126"},{"key":"61399","doi-asserted-by":"crossref","unstructured":"van de Rijn M, Lerch PG, Knowles RW, Terhorst C. The thymic differentiation markers T6 and M241 are two unusual MHC class I antigens. J Immunol. 1983; 131(2):851-855.","DOI":"10.4049\/jimmunol.131.2.851"},{"key":"61400","doi-asserted-by":"crossref","unstructured":"Martin LH, Calabi F, Lefebvre FA, Bilsland CA, Milstein C. Structure and expression of the human thymocyte antigens CD1a, CD1b, and CD1c. Proc Natl Acad Sci U S A. 1987; 84(24):9189-9193.","DOI":"10.1073\/pnas.84.24.9189"},{"key":"61401","doi-asserted-by":"crossref","unstructured":"Amiot M, Dastot H, Schmid M, Bernard A, Boumsell L. Analysis of CD1 molecules on thymus cells and leukemic T lymphoblasts identifies discrete phenotypes and reveals that CD1 intermolecular complexes are observed only on normal cells. Blood. 1987; 70(3):676-685.","DOI":"10.1182\/blood.V70.3.676.bloodjournal703676"},{"key":"61402","doi-asserted-by":"crossref","unstructured":"Pui CH, Behm FG, Singh B. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 1990; 75(1):174-179.","DOI":"10.1182\/blood.V75.1.174.174"},{"key":"61403","doi-asserted-by":"crossref","unstructured":"Niehues T, Kapaun P, Harms DO. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999; 13(4):614-617.","DOI":"10.1038\/sj.leu.2401382"},{"key":"61404","doi-asserted-by":"crossref","unstructured":"van Grotel M, Meijerink JP, Van Wering ER. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 2008; 22(1):124-131.","DOI":"10.1038\/sj.leu.2404957"},{"key":"61405","doi-asserted-by":"crossref","unstructured":"Sanchez-Martinez D, Baroni ML, Gutierrez-Aguera F. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019; 133(21):2291-2304.","DOI":"10.1182\/blood-2018-10-882944"},{"key":"61406","doi-asserted-by":"crossref","unstructured":"Sims JE, Tunnacliffe A, Smith WJ, Rabbitts TH. Complexity of human T-cell antigen receptor beta-chain constant- and variable-region genes. Nature. 1984; 312(5994):541-545.","DOI":"10.1038\/312541a0"},{"key":"61407","doi-asserted-by":"crossref","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12):1416-1423.","DOI":"10.1038\/nm.4444"},{"key":"61408","doi-asserted-by":"crossref","unstructured":"Campana D, Thompson JS, Amlot P, Brown S, Janossy G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J Immunol. 1987; 138(2):648-655.","DOI":"10.4049\/jimmunol.138.2.648"},{"key":"61409","doi-asserted-by":"crossref","unstructured":"Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. 1980; 77(3):1588-1592.","DOI":"10.1073\/pnas.77.3.1588"},{"key":"61410","doi-asserted-by":"crossref","unstructured":"Huang S, Terstappen LWMM. Lymphoid and myeloid differentiation of single human CD34+, HLA-Dr+, CD38-hematopoietic stem cells. Blood. 1994; 83(6):1515-1526.","DOI":"10.1182\/blood.V83.6.1515.bloodjournal8361515"},{"key":"61411","doi-asserted-by":"crossref","unstructured":"Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997; 94(10):5320-5325.","DOI":"10.1073\/pnas.94.10.5320"},{"key":"61412","doi-asserted-by":"crossref","unstructured":"Taussig DC, Vargaftig J, Miraki-Moud F. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010; 115(10):1976-1984.","DOI":"10.1182\/blood-2009-02-206565"},{"key":"61413","doi-asserted-by":"crossref","unstructured":"Tembhare PR, Sriram H, Khanka T. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer. 2020; 8(1):e000630.","DOI":"10.1136\/jitc-2020-000630"},{"key":"61414","doi-asserted-by":"crossref","unstructured":"Ofran Y, Ringelstein-Harlev S, Slouzkey I. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia. Leukemia. 2020; 34(1):293-295.","DOI":"10.1038\/s41375-019-0548-z"},{"key":"61415","doi-asserted-by":"crossref","unstructured":"Bride KL, Vincent TL, Im SY. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018; 131(9):995-999.","DOI":"10.1182\/blood-2017-07-794214"},{"key":"61416","doi-asserted-by":"crossref","unstructured":"Mihara K, Yanagihara K, Takigahira M. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother. 2009; 32(7):737-743.","DOI":"10.1097\/CJI.0b013e3181adaff1"},{"key":"61417","doi-asserted-by":"crossref","unstructured":"Mihara K, Yanagihara K, Takigahira M. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol. 2010; 151(1):37-46.","DOI":"10.1111\/j.1365-2141.2010.08297.x"},{"key":"61418","doi-asserted-by":"crossref","unstructured":"Mihara K, Bhattacharyya J, Kitanaka A. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia. 2012; 26(2):365-367.","DOI":"10.1038\/leu.2011.205"},{"key":"61419","doi-asserted-by":"crossref","unstructured":"Drent E, Groen RW, Noort WA. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016; 101(5):616-625.","DOI":"10.3324\/haematol.2015.137620"},{"key":"61420","doi-asserted-by":"crossref","unstructured":"Glisovic-Aplenc T, Diorio C, Chukinas JA. CD38 as a panhematologic target for chimeric antigen receptor T cells. Blood Adv. 2023; 7(16):4418-4430.","DOI":"10.1182\/bloodadvances.2022007059"},{"key":"61421","doi-asserted-by":"crossref","unstructured":"Mamonkin M, Brenner MK, Heslop H. Safety and antitumor activity of CD5 CAR T-cells in patients with relapsed\/ refractory T-cell malignancies. Blood. 2019; 134(Supplement_1):199.","DOI":"10.1182\/blood-2019-129559"},{"key":"61422","doi-asserted-by":"crossref","unstructured":"Ruella M, Xu J, Barrett DM. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503.","DOI":"10.1038\/s41591-018-0201-9"},{"key":"61423","doi-asserted-by":"crossref","unstructured":"Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood. 1992; 79(9):2370-2377.","DOI":"10.1182\/blood.V79.9.2370.2370"},{"key":"61424","doi-asserted-by":"crossref","unstructured":"Winter SS, Sweatman JJ, Lawrence MB. Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow stroma requires involvement of LFA-1 and ICAM-1. Br J Haematol. 2001; 115(4):862-871.","DOI":"10.1046\/j.1365-2141.2001.03182.x"},{"key":"61425","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Hancock ML. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002; 100(7):2399-2402.","DOI":"10.1182\/blood-2002-04-1130"},{"key":"61426","doi-asserted-by":"crossref","unstructured":"van der Velden V, Jacobs DC, Wijkhuijs AJ. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia, but not in precursor-B-ALL. Leukemia. 2002; 16(8):1432-1436.","DOI":"10.1038\/sj.leu.2402636"},{"key":"61427","doi-asserted-by":"crossref","unstructured":"Muller S, Schulz A, Reiss U. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant. 1999; 24(6):575-581.","DOI":"10.1038\/sj.bmt.1701970"},{"key":"61428","doi-asserted-by":"crossref","unstructured":"Dholaria B, Savani BN, Labopin M. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020; 105(1):47-58.","DOI":"10.3324\/haematol.2019.219790"},{"key":"61429","doi-asserted-by":"crossref","unstructured":"Pan J, Tan Y, Wang G. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: firstin-human, phase I trial. J Clin Oncol. 2021; 39(30):3340-3351.","DOI":"10.1200\/JCO.21.00389"},{"key":"61430","doi-asserted-by":"crossref","unstructured":"Tan Y, Shan L, Zhao L. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023; 16(1):34.","DOI":"10.1186\/s13045-023-01427-3"},{"key":"61431","doi-asserted-by":"crossref","unstructured":"Li Z, An N, Yang K. Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy. Transplant Cell Ther. 2023; 29(3):167-173.","DOI":"10.1016\/j.jtct.2022.11.013"},{"key":"61432","doi-asserted-by":"crossref","unstructured":"Li S, Wang X, Yuan Z. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res. 2021; 27(5):1242-1246.","DOI":"10.1158\/1078-0432.CCR-20-1271"},{"key":"61433","doi-asserted-by":"crossref","unstructured":"Hu Y, Zhou Y, Zhang M. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022; 32(11):995-1007.","DOI":"10.1038\/s41422-022-00721-y"},{"key":"61434","doi-asserted-by":"crossref","unstructured":"Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006; 6(5):383-393.","DOI":"10.1038\/nri1842"},{"key":"61435","doi-asserted-by":"crossref","unstructured":"Chen W, Shi H, Liu Z. Single-cell transcriptomics reveals immune reconstitution in patients with R\/R T-ALL\/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res. 2023; 29(8):1484-1495.","DOI":"10.1158\/1078-0432.CCR-22-2924"},{"key":"61436","doi-asserted-by":"crossref","unstructured":"Vega F, Medeiros LJ. A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. Human Pathol. 2020; 102:104-116.","DOI":"10.1016\/j.humpath.2020.05.006"},{"key":"61437","doi-asserted-by":"crossref","unstructured":"Shah NN, Johnson BD, Schneider D. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575.","DOI":"10.1038\/s41591-020-1081-3"},{"key":"61438","doi-asserted-by":"crossref","unstructured":"Del Bufalo F, Becilli M, Rosignoli C. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood. 2023; 142(2):146-157.","DOI":"10.1182\/blood.2023020023"},{"key":"61439","doi-asserted-by":"crossref","unstructured":"Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2017; 545(7655):423-431.","DOI":"10.1038\/nature22395"},{"key":"61440","doi-asserted-by":"crossref","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Rev Clin Oncol. 2020; 17(3):147-167.","DOI":"10.1038\/s41571-019-0297-y"},{"key":"61441","doi-asserted-by":"crossref","unstructured":"An N, Hou YN, Zhang QX. Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells. Mol Pharm. 2018; 15(10):4577-4588.","DOI":"10.1021\/acs.molpharmaceut.8b00584"},{"key":"61442","doi-asserted-by":"crossref","unstructured":"Hill LC, Rouce RH, Smith TS. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies. Blood. 2019; 134(Supplement_1):199.","DOI":"10.1182\/blood-2019-129559"},{"key":"61443","doi-asserted-by":"crossref","unstructured":"Ghobadi A, Aldoss I, Maude SL. Phase 1\/2 dose-escalation study of anti-CD7 allogenic CAR-T cell in relapsed or refractory T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma. HemaSphere. 2023; 7(10):e957.","DOI":"10.1097\/01.HS9.0000968336.17893.02"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283848\/76989","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283848\/77042","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11595\/76989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:35Z","timestamp":1794045995000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":131,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283848","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}